Zhejiang Huahai’s HB0034 Meets Primary Endpoint in GPP Study
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its multi-center, double-blinded, randomized, placebo-parallel...
Drug
Fosun Pharma’s 24-Valent Pneumococcal Vaccine Receives NMPA Approval for Phase I Trial
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd’s (SHA: 600196, HKG: 2196) subsidiary Fosun Adgenvax (Chengdu)...
Suzhou Abogen’s RSV mRNA Vaccine IND Approved by China’s CDE
China-based nucleic acid drug developer Suzhou Abogen Biosciences announced that the Investigational New Drug (IND)...
BeiGene’s Tevimbra Receives FDA Approval for ESCC Treatment
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a multinational oncology company planning to change...
AstraZeneca and Daiichi Sankyo’s Enhertu Shows Positive Results in Phase III Study
Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced positive topline results from the...
Genentech’s TNKase Approved by FDA for Acute Ischemic Stroke Treatment
Genentech, a subsidiary of Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY), announced that its thrombolytic...
Eisai’s Lecanemab Rejected by Australia’s TGA for Early Alzheimer’s Treatment
Japan-based Eisai Co., Ltd (TYO: 4523) announced that the Therapeutic Goods Administration (TGA) of Australia...
Fapon Biopharma’s FP008 Receives FDA Approval for Clinical Trials
China-based Fapon Biopharma announced that it has received clinical trial approval from the US Food...
GSK’s Depemokimab Accepted for FDA Review as Ultra-Long-Acting Biologic
GSK plc (LON: GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA)...
Juvestar and Raziel Therapeutics Launch Phase III Study for RZL-012 in China
Juvestar Biotech Co., Ltd., a subsidiary of China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:...
Zai Lab’s Augtyro Receives TFDA Approval for ROS1-Positive NSCLC and NTRK Fusion Solid Tumors
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that it has received marketing...
Huadong Medicine’s HDM1005 Receives NMPA Approval for Clinical Trials
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...
Tonghua Dongbao’s Tongboli Under GMP Inspection in Egypt
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced that the on-site Good Manufacturing Practice (GMP) inspection...
United Laboratories’ UBT251 Receives FDA Green Light for Phase II CKD Study
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) announced that it has received approval...
CStone Pharmaceuticals Doses First Patient in CS2009 Phase I Study for Solid Tumors
China-based CStone Pharmaceuticals (HKG: 2616) announced the first patient dosing in a global, multi-center Phase...
Laekna’s LAE120 Receives FDA Approval for Solid Tumor Clinical Trials
Sino-US biotech company Laekna, Inc. (HKG: 2105) announced that it has received clinical trial approval...
SynerK’s SNK-2726 Gets FDA Green Light for Phase I Hypertension Study
SynerK, an RNA-targeted therapy developer with operations in Boston, US, and Beijing and Suzhou, China,...
Innovent Biologics Doses First Patient in IBI363 Melanoma Study vs Keytruda
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the pivotal regulatory...
Eyebright Medtech Plans Private Placement to Expand Contact Lens Production
China-based Eyebright Medical Technology (Beijing) Co., Ltd. (SHA: 688050), an ophthalmic medical device manufacturer, announced...
Sinocelltech’s Finotonlimab Gets NMPA Approval for Liver Cancer Treatment
China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received another indication approval from...